Health
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstractsIndependent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety, and vonoprazan use post endoscopic submucosal dissection (ESD)Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-3
About this update from Phathom Pharmaceuticals, Inc.
[{"type":"image","alt":"Phathom Pharmaceuticals","displaySize":"","headline":null,"caption":"Phathom Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/08e599db31de5fdce3058dc9a47e4693"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6SL2C6WY7yKSFTq44iAahw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/08e599db31de5fdce3058dc9a47e4693","width":300,"height":87},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/6SL2C6WY7yKSFTq44iAahw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/08e599db31de5fdce3058dc9a47e4693","width":300,"height":87}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Independent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety, and vonoprazan use post endoscopic submucosal dissection (ESD)","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-301 trial recognized by DDW as a Poster of Distinction","length":168,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":553,"olType":false},{"type":"text","content":"FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today highlighted the growing body of clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA® (vonoprazan), at Digestive Disease Week (DDW) 2026, held May 2–5, 2026 in Chicago, Illinois. Phathom presented three posters at the meeting, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study that was recognized by DDW as a Poster of Distinction, a designation reserved for abstracts of notable scientific merit. Vonoprazan was also the subject of 28 additional independent, investigator-initiated abstracts...